110 related articles for article (PubMed ID: 37653116)
1. Retraction Note: Therapeutic potential of targeting IRES-dependent c-myc translation in multiple myeloma cells during ER stress.
Shi Y; Yang Y; Hoang B; Bardeleben C; Holmes B; Gera J; Lichtenstein A
Oncogene; 2023 Sep; 42(40):3016. PubMed ID: 37653116
[No Abstract] [Full Text] [Related]
2. Therapeutic potential of targeting IRES-dependent c-myc translation in multiple myeloma cells during ER stress.
Shi Y; Yang Y; Hoang B; Bardeleben C; Holmes B; Gera J; Lichtenstein A
Oncogene; 2016 Feb; 35(8):1015-24. PubMed ID: 25961916
[TBL] [Abstract][Full Text] [Related]
3. Critical Role for Cap-Independent c-MYC Translation in Progression of Multiple Myeloma.
Shi Y; Sun F; Cheng Y; Holmes B; Dhakal B; Gera JF; Janz S; Lichtenstein A
Mol Cancer Ther; 2022 Apr; 21(4):502-510. PubMed ID: 35086951
[TBL] [Abstract][Full Text] [Related]
4. Annexin A2 binds the internal ribosomal entry site of c-
Strand E; Hollås H; Sakya SA; Romanyuk S; Saraste MEV; Grindheim AK; Patil SS; Vedeler A
RNA Biol; 2021 Oct; 18(sup1):337-354. PubMed ID: 34346292
[TBL] [Abstract][Full Text] [Related]
5. Upregulated c-myc expression in multiple myeloma by internal ribosome entry results from increased interactions with and expression of PTB-1 and YB-1.
Cobbold LC; Wilson LA; Sawicka K; King HA; Kondrashov AV; Spriggs KA; Bushell M; Willis AE
Oncogene; 2010 May; 29(19):2884-91. PubMed ID: 20190818
[TBL] [Abstract][Full Text] [Related]
6. A mutation in the c-myc-IRES leads to enhanced internal ribosome entry in multiple myeloma: a novel mechanism of oncogene de-regulation.
Chappell SA; LeQuesne JP; Paulin FE; deSchoolmeester ML; Stoneley M; Soutar RL; Ralston SH; Helfrich MH; Willis AE
Oncogene; 2000 Sep; 19(38):4437-40. PubMed ID: 10980620
[TBL] [Abstract][Full Text] [Related]
7. Mechanistic Target of Rapamycin (mTOR) Inhibition Synergizes with Reduced Internal Ribosome Entry Site (IRES)-mediated Translation of Cyclin D1 and c-MYC mRNAs to Treat Glioblastoma.
Holmes B; Lee J; Landon KA; Benavides-Serrato A; Bashir T; Jung ME; Lichtenstein A; Gera J
J Biol Chem; 2016 Jul; 291(27):14146-14159. PubMed ID: 27226604
[TBL] [Abstract][Full Text] [Related]
8. Eukaryotic translation initiation factor 4GI and p97 promote cellular internal ribosome entry sequence-driven translation.
Hundsdoerfer P; Thoma C; Hentze MW
Proc Natl Acad Sci U S A; 2005 Sep; 102(38):13421-6. PubMed ID: 16174738
[TBL] [Abstract][Full Text] [Related]
9. c-Myc protein synthesis is initiated from the internal ribosome entry segment during apoptosis.
Stoneley M; Chappell SA; Jopling CL; Dickens M; MacFarlane M; Willis AE
Mol Cell Biol; 2000 Feb; 20(4):1162-9. PubMed ID: 10648601
[TBL] [Abstract][Full Text] [Related]
10. L-Myc protein synthesis is initiated by internal ribosome entry.
Jopling CL; Spriggs KA; Mitchell SA; Stoneley M; Willis AE
RNA; 2004 Feb; 10(2):287-98. PubMed ID: 14730027
[TBL] [Abstract][Full Text] [Related]
11. Granulocyte-macrophage colony-stimulating factor and interleukin-3 induce cell cycle progression through the synthesis of c-Myc protein by internal ribosome entry site-mediated translation via phosphatidylinositol 3-kinase pathway in human factor-dependent leukemic cells.
Kobayashi N; Saeki K; Yuo A
Blood; 2003 Nov; 102(9):3186-95. PubMed ID: 12855588
[TBL] [Abstract][Full Text] [Related]
12. Cyclin D1 and c-myc internal ribosome entry site (IRES)-dependent translation is regulated by AKT activity and enhanced by rapamycin through a p38 MAPK- and ERK-dependent pathway.
Shi Y; Sharma A; Wu H; Lichtenstein A; Gera J
J Biol Chem; 2005 Mar; 280(12):10964-73. PubMed ID: 15634685
[TBL] [Abstract][Full Text] [Related]
13. Identification of cardiac glycoside molecules as inhibitors of c-Myc IRES-mediated translation.
Didiot MC; Hewett J; Varin T; Freuler F; Selinger D; Nick H; Reinhardt J; Buckler A; Myer V; Schuffenhauer A; Guy CT; Parker CN
J Biomol Screen; 2013 Apr; 18(4):407-19. PubMed ID: 23150017
[TBL] [Abstract][Full Text] [Related]
14. Members of the poly (rC) binding protein family stimulate the activity of the c-myc internal ribosome entry segment in vitro and in vivo.
Evans JR; Mitchell SA; Spriggs KA; Ostrowski J; Bomsztyk K; Ostarek D; Willis AE
Oncogene; 2003 Sep; 22(39):8012-20. PubMed ID: 12970749
[TBL] [Abstract][Full Text] [Related]
15. The feed-forward loop between YB-1 and MYC is essential for multiple myeloma cell survival.
Bommert KS; Effenberger M; Leich E; Küspert M; Murphy D; Langer C; Moll R; Janz S; Mottok A; Weissbach S; Rosenwald A; Bargou R; Bommert K
Leukemia; 2013 Feb; 27(2):441-50. PubMed ID: 22772059
[TBL] [Abstract][Full Text] [Related]
16. Translational control of the undifferentiated phenotype in ER‑positive breast tumor cells: Cytoplasmic localization of ERα and impact of IRES inhibition.
Vaklavas C; Zinn KR; Samuel SL; Meng Z; Grizzle WE; Choi H; Blume SW
Oncol Rep; 2018 Jun; 39(6):2482-2498. PubMed ID: 29620220
[TBL] [Abstract][Full Text] [Related]
17. Regulation of D-cyclin translation inhibition in myeloma cells treated with mammalian target of rapamycin inhibitors: rationale for combined treatment with extracellular signal-regulated kinase inhibitors and rapamycin.
Frost P; Shi Y; Hoang B; Gera J; Lichtenstein A
Mol Cancer Ther; 2009 Jan; 8(1):83-93. PubMed ID: 19139116
[TBL] [Abstract][Full Text] [Related]
18. Targeting an MDM2/MYC Axis to Overcome Drug Resistance in Multiple Myeloma.
Faruq O; Zhao D; Shrestha M; Vecchione A; Zacksenhaus E; Chang H
Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326742
[TBL] [Abstract][Full Text] [Related]
19. PERK mediates the IRES-dependent translational activation of mRNAs encoding angiogenic growth factors after ischemic stress.
Philippe C; Dubrac A; Quelen C; Desquesnes A; Van Den Berghe L; Ségura C; Filleron T; Pyronnet S; Prats H; Brousset P; Touriol C
Sci Signal; 2016 May; 9(426):ra44. PubMed ID: 27141928
[TBL] [Abstract][Full Text] [Related]
20. Targeting c-Myc Unbalances UPR towards Cell Death and Impairs DDR in Lymphoma and Multiple Myeloma Cells.
Arena A; Romeo MA; Benedetti R; Gilardini Montani MS; Cirone M
Biomedicines; 2022 Mar; 10(4):. PubMed ID: 35453482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
